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 Reevaluation of the University of Wisconsin 2- Year Protocol for Treating Canine 
Lymphosarcoma 
 
Abstract 
This retrospective study investigated a population of 96 dogs with newly diagnosed 
malignant lymphosarcoma that were treated with the commonly used University of 
Wisconsin-Madison (UW-M) chemotherapy protocol. Pretreatment characteristics were 
analyzed to determine prognostic factors. Dogs with higher World Health Organization 
(WHO) stages (including stage IV) and dogs with hypercalcemia were at significantly higher 
risk of relapse (P = 0.018, and P = 0.016, respectively). Dose reduction, treatment delays and 
prior therapy with corticosteroids were not associated with clinical outcome. First remission 
duration of 270 days was similar to historically reported data. Overall survival time of 218 
days was much shorter than historical data.  
 
 
 
(This paper was written in the context of a doctoral thesis) 
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Introduction 
Lymphosarcoma, neoplasia arising from lymphoreticular cells, is one of the 
malignancies most likely to respond to chemotherapy, and it is also one of the most common 
neoplasms of the dog.1 Various chemotherapeutic regimens have been used and usually 
consist of multiple drugs.2,3 Response rates of 80 to 90% with median survival times of 250 to 
300 days have been reported.2,4 Numerous studies have been undertaken to identify 
prognostic factors relating to response to treatment, length of remission, and survival times. 
Results from these studies have varied.5,6-11 One common treatment regime used for canine 
lymphosarcoma is the University of Wisconsin (UW)-Madison 2-year chemotherapy 
protocol. Studies with limited numbers of dogs have investigated survival times of dogs 
treated with this protocol.6,12,13 
The objective of this retrospective study was to evaluate signalment, prognosis, and 
prognostic factors in a previously unreported canine population that underwent treatment with 
the UW-Madison chemotherapy protocol for lymphosarcoma.  
 
Materials and Methods 
Case Selection 
Medical records were searched at the Small Animal Clinic, Veterinary School, 
University of Zurich from April 1996 to December 2002 for dogs with definitive cytologic or 
histopathologic diagnosis of lymphosarcoma, that had received no chemotherapy except 
corticosteroids before being treated with the UW-Madison 2- year chemotherapy protocol. 
Diagnosis of lymphosarcoma was made on the basis of cytologic examination of needle 
aspirates, and/or histologic examination of surgically excised lymph nodes or other tissue 
samples. If any question concerning the accuracy of a cytological diagnosis arose, histological 
examination of a tissue specimen was performed.  
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Staging was done using the modified World Health Organization (WHO) staging 
system for canine lymphosarcoma and consisted of a complete blood count (CBC), a serum 
biochemistry profile, urinalysis, and thoracic radiography.2 Whenever the physical 
examination and/or the serum chemistry profile suggested visceral involvement,  
abdominal ultrasonography (n=27) or radiography (n=31) was performed. Leukemia was 
diagnosed based on bone marrow evaluation (n=6) or cytologic examination of blood smears 
(n=11). The WHO staging system was modified as described in a previous study, so that 
extranodal lymphosarcomas were considered a separate stage.12 Stage VI was created based 
on the fact that extranodal lymphosarcomas do not clinically behave like stage V 
lymphosarcomas [Table 1]. 
The dogs were further divided into substage a (without constitutional signs), and 
substage b (with clinical signs of illness). Factors that were investigated included age, gender, 
breed, weight, clinical stage and substage, anatomical location, presence of hypercalcemia 
(reference range 9.6 – 11.2 mg/dl) or hyperbilirubinemia (reference range 0.145 – 0.44 
mg/dl), hematocrit, hemoglobin, presence of neurologic signs, prior treatments, time between 
onset of signs until first treatment, toxicities associated with chemotherapy, dose reductions 
and alterations in therapy, and therapy instituted at relapse. Month of presentation and month 
of relapse were also noted, in order to evaluate for seasonality, a factor anecdotally reported 
in dogs. Because absolute thrombocyte counts were not available in most cases (i.e., platelet 
numbers were indicated as sufficient, high or low), this parameter was not evaluated. 
Immunophenotyping was not routinely performed owing to cost concerns.  
 
Treatment Protocol 
The doses and frequency of drugs used in the UW-Madison protocol are shown in 
Table 2. In 22 dogs the first dose of vincristineb was reduced to 0.5 mg/m2 owing to concerns 
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of increased toxicity in the first week of therapy when L-asparaginase and vincristine are 
combined.14,15 
 
Side Effects 
Toxicity was assessed based on the National Cancer Institute (NCI) toxicity grading 
system for hematological and gastrointestinal toxicities [Table 3]. Owners were questioned as 
to whether the dog had any signs of gastrointestinal toxicosis (e.g., anorexia, vomiting, or 
diarrhea) and whether the dog’s demeanor had changed. In cases of myelosuppression (i.e., a 
neutrophil count <3000/µL), treatment was delayed for a week and subsequent doses of that 
drug were reduced. If severe drug-induced gastrointestinal toxicosis developed, therapy was 
withheld and the dosage of the agent thought to be the cause of toxicosis was reduced. Only 
treatment delays owing to toxicity were statistically evaluated.  
 
Responses and Outcomes 
Complete remission was defined as the disappearance of all clinical evidence of 
disease on physical examination, radiography, ultrasonography, CBC or biochemistries.  
A partial response was defined as a decrease in tumor volume ≥50%, with no new lesions. 
Stable disease was defined as no change in tumor burden or <50% decrease in tumor volume. 
Progressive disease was defined as appearance of new lesions and/or tumor growth.  
The first remission duration was defined as the time between recognition of a 
complete remission until evidence of relapse. Overall survival time was defined as time from 
the first chemotherapy treatment until death from lymphosarcoma or treatment. Survival time 
was determined by review of the medical record or by contact with the referring veterinarian 
or owner. 
 
Statistical Analysis 
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All dogs entering the study were included in analysis for overall survival time (n=96). 
Dogs that received only one treatment and were euthanized or died were evaluated despite not 
completing the induction protocol. Only dogs that achieved remission were included in 
remission duration calculations (n=76). Discrete factors evaluated for significance included 
gender, breed, clinical stage and substage, anatomical location, presence of hypercalcemia, 
presence of neurologic signs, prior treatments, toxicities experienced, dose reductions, 
alterations in therapy, and therapy at relapse. Continuous factors included age, body weight, 
hyperbilirubinemia, hematocrit, hemoglobin, and time between onset of disease until 
treatment, and toxicities experienced. Univariate analysis to assess the prognostic value of the 
different discrete cofactors was performed by the Kaplan-Meier method, together with the log 
rank or “Breslow” test.16 The associations between two discrete covariates were evaluated by 
Fisher’s exact test using a computerized software programa. In order to compare means of a 
continuous variable with respect to a factor with only two levels, the Mann-Whitney U-test 
was applied.16 For two continuous covariates, Peareson’s correlation was computed with a 
95% confidence interval.16 Month of presentation and month of relapse were evaluated by the 
goodness of fit Chi square-test.17 Variables that were identified to be significant in univariate 
analysis were included in a multivariate Cox proportional hazards model regression analysis 
with a forward and backward step selection, for both survival and remission.16 Results were 
considered to be significant with P values <0.05. 
Dogs were censored in analysis of remission duration if they were in remission at the 
end of the study, were lost to follow-up, or had died from other causes while in remission. 
Dogs were censored in analysis of survival if they were lost to follow-up, died from causes 
unrelated to lymphosarcoma or chemotherapy, or were alive at the end of the study period.  
 
Results 
Case Data 
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Ninety-six dogs met the inclusion criteria for the study. The median age at diagnosis 
was 7.7 years (range 0.5-14; mean 7.63 ± 0.3 years). Forty-six dogs were females (32  
spayed) and 50 were males (18 castrated). The most common breeds included the Bernese 
mountain dog (n=11), rottweiler (n=5), German shepherd dog (n=5), Doberman pinscher 
(n=4), and Labrador retriever (n=4). Forty seven dogs (49%) were comprised of 30 additional 
breeds, and 20 animals were mixed breed dogs (21%). The median weight was 31 kg (range 4 
to 78 kg; mean 30.0 ± 1.5 kg). Stage distribution is shown in Table 4.   
Seventeen dogs (18%) were leukemic, 17 (18%) had cranial mediastinal involvement, 
and six (6%) had pulmonic involvement. The sites of involvement of the nine stage VI dogs 
were gastrointestinal (n=3), ocular (n=3), nasal (n=1), and spinal (n=2). Fifteen dogs (16%) 
had hypercalcemia (median 14.8 mg/dL, range 12.5 to 18.8 mg/dL), eight of which had 
mediastinal involvement (stage I, mediastinum only [n=1], stage II [n=1], stage III [n=4], and 
stage IV [n=2]).  Hypercalcemic dogs without mediastinal involvement were staged as stages  
III (n=5), and IV (n=2). Nine dogs had hyperbilirubinemia. The median bilirubin level of all 
dogs measured was 0.19 mg/dL (range 0.005 to 14.15 mg/dL). The median hematocrit  
was 42.0 ± 0.8 % (range 18 to 61 %); the median hemoglobin was 14.4 ± 0.3g/dL (range 3.8 
to 21 g/dL). Three dogs were presented with neurologic signs. Correlations were found 
between WHO stage and age (P = 0.0002), WHO stage and hypercalcemia (P=0.0227), as 
well as age and weight (P = 0.021). Hypercalcemia was found in younger dogs in lower 
stages. Higher WHO stages were associated with greater age and smaller body weights.  
Fifty-four dogs received prior treatments that consisted of antibiotics (n=24), 
corticosteriods (n=14), antibiotics and corticosteroids (n=11), or alternative medications, such 
as mistletoe or immunomodulatory drugs (n=5). Median duration of pretreatment was 13.5± 
2.4 days (range 1 to 81 days). Median time from appearance of first clinical signs until 
treatment was 18 ± 2.8 days (range 4 to 165 days). The initial diagnoses were highest in the 
months of July (n=10), August (n=10), November (n=15), and December (n=10) but this 
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pattern was not statistically significant (χ2- test = 16.05; P = 0.1393). A higher tendency of 
relapse was detected in the months of May (n=8), June (n=7), July (n=7), and September 
(n=9), and October (n=7) (χ2- test = 15.75; P = 0.1507). In the years from 1996 until the end 
of the study in 2004, not one dog relapsed in the month of April.  
 
Side Effects 
Side effects and dosage reductions are summarized in Tables 5 and 6. Side effects 
were most frequently experienced after the first week of treatment. The five dogs that died 
after their first treatment were all substage b in stage III (n=2), stage IV (n=2), and stage VI 
(n=1). Twelve dogs suffered bone marrow toxicity after week 1 and 26 dogs had 
gastrointestinal toxicities; some dogs suffered concurrently from both. Sixteen dogs had to be 
hospitalized (mean duration 2.9 ± 0.7 days, range 1 to 11 days) for drug-induced toxicity. Six 
hospitalizations occurred after week 1 (6.2%). Eleven dogs were hospitalized once; five dogs 
were hospitalized more than once (two or three times). The drug that most frequently caused 
side effects was vincristine (66 dogs). Thirteen dogs exhibited gastrointestinal toxicity after 
the first doxorubicin treatment in week 4. In one case, vincristine-induced neuropathy was 
strongly suspected and vincristine was discontinued at week 15 of the protocol.  
Treatment delays owing to toxicity usually occurred during the induction phase (n=39). 
Remission duration was not significantly associated with dosage reductions (n=43; P = 0.248) 
or treatment delays (n=35; P = 0.233). Specifically for the 22 dogs that received vincristine at 
0.5 mg/m2 in week 1, there was no statistically significant influence on remission duration 
(n=19; P = 0.10) and toxicities in week 1 for this group of dogs included gastrointestinal  
(n=6, 27%), bone marrow (n=3, 14 %),  hospitalizations (n=2, 9%), and death (n=1, 4%). 
 
Treatment Response 
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Seventy-six dogs (79%) experienced a complete remission. Dogs that did not achieve 
a complete response had various stages of disease, namely stage II (n=1), stage III (n=6), 
stage IV (n=6), stage V (n=4), and stage VI (n=3). The median duration of the first remission 
was 270 ± 20.3days. Breed and gender status had no statistical influence on remission. 
Univariate variables that significantly increased the likelihood of relapse were hypercalcemia 
(P = 0.017), and higher initial stage classification (stages IV, V and VI as opposed to stages I, 
II, and III; P = 0.018). 
Of the 15 dogs that were hypercalcemic, 11 had a complete response. The median 
duration of the first remission for the 11 dogs was only 139 ± 26.3 days as opposed to 296 ± 
31.2 days for dogs that were normocalcemic. Hypercalcemia did not influence the likelihood 
of achieving remission. In univariate analysis the presence of leukemia resulted in shorter 
remission duration. Leukemic dogs had a median remission duration of 172 ± 9 days, as 
opposed to 296± 30.5 days for non-leukemic dogs (P = 0.02). There was a tendency for 
longer remission duration with dogs in substage a (308 ± 43.7 days), versus substage b (176 ± 
55.3 days), but substage alone was not statistically significant (P = 0.16). Being classified as 
substage a was not a significant predictor of the likelihood of remission (P = 0.21). The time 
period between onset of the disease and first chemotherapeutic administration was not 
associated with achievement or duration of remission (P = 0.90). Of the 19 dogs pretreated 
with corticosteroids, remission duration was not significantly impacted (P = 0.70).  
Evaluation of multiple Cox regression by the backward search procedure revealed 
only two factors that remained statistically significant, namely elevated calcium (P = 0.037; 
Figure 1), and higher WHO classification of stage (P = 0.016; Figure 2). Forward stepwise 
analysis revealed leukemia as a negative prognostic marker (P = 0.011), together with 
hypercalcemia (P = 0.007).  
In 34 dogs a second remission was attempted with either the same protocol (n=17) or 
with lomustineh (60 mg/m2 per os q 3 weeks, n=17). A number of dogs received other rescue 
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therapies, such as: mitoxantrone (n=1), actinomycin (n=1), alkeran (n=1), or no treatment 
(n=16) but were not included in the second remission analysis because of low numbers in 
each treatment group. Eighteen of 34 dogs (53%) achieved a second remission, 11 of which 
received the same protocol and seven received lomustine. A significant difference in the 
length of second remission duration was detected between those treated with the same 
protocol and those treated with lomustine, with dogs reinduced with the same protocol having 
a significantly longer overall survival time than the latter group (P = 0.008; Figure 3).  
 
Outcomes 
Three dogs were still in remission at the end of the study (845, 1336, and 1720 days 
after initial treatment). Eight dogs had died or were euthanized for causes unrelated to 
lymphosarcoma, with one dog experiencing each of the following: cardiomyopathy (week 3 
of therapy), ophthalmic disease, gastric foreign body, neurological disease, renal failure, 
osteosarcoma, orthopedic disease, and sudden death after a dental procedure. Four dogs were 
lost to follow up at 329, 456, 806, and 1333 days. The median survival time of all dogs was 
218 ± 15.90 days. Univariate analysis identified WHO substage as a significant (P = 0.004) 
prognostic indicator of overall survival time. The median overall survival time for substage a 
was 443 ± 136.1 days; the median overall survival time for substage b was 136 ± 77.3 days. 
Median overall survival time for dogs that achieved a complete remission was 322 ± 68.6 
days. 
 
Discussion 
Many findings of this study were similar to previously published results.  The median 
age and weight of the dogs was similar to other studies.12,13 The high number of intact 
females in this study may have been related to regional differences because in North 
American studies, intact females are typically underrepresented.9,14,18 In the present study 
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clinical courses experienced by intact females were similar to spayed females and males. One 
new finding was the high percentage of Bernese mountain dogs, which might indicate a 
susceptibility to lymphosarcoma for this breed. A comparison of affected dogs with the 
overall hospital population was not performed however.  
The current study identified hypercalcemia as a significant prognostic factor in 
univariate and multivariate analyses. This finding has been reported previously using 
univariate analysis in some studies, whereas other studies have reported no significance of 
hypercalcemia as a prognostic indicator.9,12,14,19 The study reported here further identified a 
negative correlation between hypercalcemia and age, and a positive association between 
hypercalcemia and lower WHO stages, a finding not previously reported. One European study 
found a WHO classification of stage IV to be a positive prognostic indicator for complete 
remission rates, whereas the present study identified stages IV, V and VI as negative 
prognostic indicators.2  
Dogs that received prednisone before starting the protocol were not at a disadvantage, 
which was similar to a former study.9  Other studies have reported that delays in therapy and 
dosage adjustments were most frequently associated with vincristine, a finding this study 
confirmed.14 Lowering the vincristine dose at week 1 did appear to decrease toxicity because 
only 14 % of the dogs in this study experienced bone marrow toxicity versus 40 %  in a study 
by Northrup et al.15  Significant toxicity did occur in the present study in dogs given a reduced 
dose of vincristine in week 1, at a level similar to previous reports on this protocol. This 
finding supported the contention that it is the combination of vincristine and L-aspariginase 
that causes bone marrow suppression more than the dose of vincristine alone.14,19   
Evaluation of vincristine toxicity in week 1 of the present study was skewed however, in  that 
certain dogs were selected to receive a reduced dose of  vincristine at week 1 (often substage 
b or higher tumor burdens and considered to be at greater risk for toxicity). Avoiding toxicity 
at week 1 allowed subsequent administration of full dosages of vincristine for the remainder 
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of the protocol (i.e., a permanent dose reduction was not made based on the dog having had a 
toxic reaction to the vincristine at week 1). Remission duration for dogs that received 
vincristine at 0.5 mg/m2 in week 1 was not shorter than the group that had the full dose, so it 
may be useful to consider a dose reduction in all dogs week 1, or at least in those that are 
considered to have the highest  risk for side effects during initial induction.   
The complete response rate of 79% was lower in this study than previously reported 
(84% to 87%) using the same protocol.12,13 One European study also observed a similar 77% 
complete response rate.2 The median duration of the first remission was comparable to other 
studies.8,12-14 The overall survival was lower at 218 days than the previously reported 357 
days.12 The lower survival may have been a real survival disadvantage or may have arisen 
from cultural differences, with European clients less likely to try multiple rescue protocols or 
choosing euthanasia sooner.  
The current study contained several limitations, including a lack of control dogs; its 
retrospective nature; differences in diagnostic testing procedures, ancillary treatments, and 
methods of evaluation and follow-up. The large number of dogs in this study helped minimize 
some of these problems. Another important point was the possibility of some degree of 
backward stage migration, as low numbers of dogs placed in stages I to III (n=43) had 
abdominal ultrasonography (n=7) or radiography (n=10) performed. As many as 26 dogs may 
have been staged lower than they actually were. When these 26 dogs were experimentally 
classified as stage IV-VI there was no longer a statistically significant difference between 
dogs in stages I to III (n=17) and dogs in stages IV to VI (n=79; P = 0.32).  
Additional factors may also have influenced treatment outcome in the dogs of this 
study. Immunophenotyping has been used to identify prognostic differences between the 
cellular subtypes of canine lymphosarcoma but was not performed in the study reported 
here.21  
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Conclusion  
Ninety-six dogs with lymphosarcoma treated with the UW-Madison 2-year chemotherapeutic 
protocol were reviewed. Hypercalcemia and higher stage of disease were confirmed as 
negative prognostic indicators independent of other variables. Treatment with corticosteroids 
prior to starting the chemotherapy protocol did not effect remission or survival. A correlation 
was found between young dogs, hypercalcemia and low-stage disease. A trend was seen for 
dogs being presented more often in winter (November and December) and summer (July and 
August). Dose reduction of vincristine in week 1 appeared to decrease toxicity without 
affecting remission length or survival and should be considered as a viable modification of 
the protocol particularly in dogs that are substage b. 
 
Footnotes 
 
a Statview version 5.0.1; SAS Institute Inc., Cary, NC 27513 
b Oncovi; Medika AG, Switzerland 
c Leunase; Farmamondo, Chiasso, Switzerland 
d Endoxan; Baxter AG, Switzerland 
e Adriablastin RD; Pfizer AG, Zürich, Switzerland 
f Leukeran; GlaxoSmithKline, Muenchenbuchsee, Switzerland 
g Methotrexat Proreo; Proreo Pharma AG, Liestal, Switzerland 
h Prava; Bristol-Myers Squibb GmbH, Baar, Switzerland
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Table 1 
Modified World Health Organization Staging of Canine Lymphosarcoma 
Stage                                 Organ Involvement 
 
  I a,b*                               Single lymph node 
 II a,b                                 Multiple lymph nodes on one side of diaphragm 
III a,b                                 Generalized lymphadenopathy 
IV a,b                                 Visceral organs 
 V a,b                                 Bone marrow, blood 
VI a,b                                 Extranodal 
*Substage a= without clinical signs of disease, Substabe b= with clinical signs of disease 
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Table 2 
University of Wisconsin 2- Year Chemotherapy Protocol for Canine Lymphosarcoma12 
Treatment Cycles                                  Drug                                       Dosage∗                                          
Cycle 1 (Induction) 
 Week 1                                                Vincristine                                0.7 mg/m2 IV†                             
 Week 1                                                L-Asparaginase                       400 IU/kg SC  
 Week 1                                                Prednisone                                  2 mg/kg PO                             
 Week 2,7                                             Cyclophosphamide                 200 mg/m2 IV/PO 
 Week 2                                                Prednisone                               1.5 mg/kg PO 
 Week 3,6,8                                          Vincristine                               0.7 mg/m2 IV 
 Week 3                                                Prednisone                               1.0 mg/kg PO 
 Week 4,9                                             Doxorubicin                             30 mg/m2 IV‡  
 Week 4                                                Prednisone                               0.5 mg/kg PO 
  
Cycle 2 (Maintenance) 
 Week 11,15,19,23                               Vincristine                               0.7 mg/m2 IV 
 Week 13, 21                                        Chlorambucil                           1.4 mg/kg PO 
 Week 17                                              Methotrexate                             0.8 mg/kg IV 
 Week 25                                              Doxorubicin                              30 mg/m2 IV‡ 
 
Cycle 3 (Maintenance) 
 Week 28, 34, 40, 46, 52, 58                Vincristine                               0.7 mg/m2 IV 
 Week 31, 43, 55                                  Chlorambucil                           1.4 mg/kg PO 
 Week 37, 61                                        Methotrexate                            0.8 mg/kg IV 
 Week 49                                              Doxorubicin                             30 mg/m2 IV‡ 
18 
 
 
Cycle 4 (Maintenance) 
 Week 65, 73, 81, 89, 97, 105, 121      Vincristine                               0.7 mg/m2 IV 
 Week 69, 85, 101, 117                        Chlorambucil                           1.4 mg/kg PO 
 Week 77, 93, 109                                Methotrexate                            0.8 mg/kg IV 
 
∗IV=Intravenous; SC=Subcutaneous; PO=Orally 
†Initiated therapy at 0.5 mg/m2 if dog had a large tumor burden or was clinically ill.  
‡Delivered in 0.9% saline solution over 1 hour; 1 mg/kg dose for dogs < 10 kg.  
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Table 3 
National Cancer Institute Toxicity Scoring Scheme for Chemotherapy Related Side Effects 
 
Type of Toxicity                            Abnormalities∗                                    Score† 
 
Bone marrow                       WBC < 3,000     N < 1,500                               H1 
                                             WBC < 2,000     N < 1,000                               H2 
                                             WBC < 1,500     N < ,800                                 H3 
                                             WBC < 1,000     N < ,500                                 H4 
 
Gastrointestinal                    Nausea, anorexia                                              G1 
 
                                             Vomiting 1 to 5 times per day 
                                             Diarrhea 5 to 7 times per day                            G2 
                                             < 5% weight loss 
 
                                             Vomiting 6 to 10 times per day 
                                             Diarrhea  > 7 times per day                               G3 
                                             5 to 10% weight loss 
 
                                             > 10% weight loss                                             G4 
∗WBC=Peripheral white blood cells/µL; N= Peripheral neutrophils/µL 
†H= hematological; G= gastrointestinal 
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Table 4 
World Health Organization Stage and Substage Distribution 
of 96 Dogs with Lymphosarcoma 
Stage   Substage               No. Dogs              Percentage (%) 
 
 I                 a                            2                          2.1 
                   b                            1                           1 
 
II                 a                            3                          3.1     
                   b                             1                          1 
 
III                a                           19                       19.8 
                    b                           17                       17.7 
 
IV                a                            9                          9.4 
                    b                           19                       19.8 
 
 V                 a                           7                          7.3 
                    b                            9                          9.4 
 
VI                 a                           1                            1 
                     b                           8                          8.4                 
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Table 5 
Toxicities Experienced with the University of Wisconsin 2-Year 
Chemotherapy Protocol for Canine Lymphosarcoma 
 
Type of Toxicity∗                     No. Dogs               Percentages (%) 
 
Bone marrow 
H1                                                        3                                 3.1 
H2                                                        2                                 2.1 
H3                                                        3                                 3.1 
H4                                                        6                                 6.3 
 
Gastrointestinal 
G1                                                        8                                 8.3 
G2                                                       27                              28.1 
G3                                                       15                              15.6 
G4                                                        3                                 3.1 
 
Other Toxicities 
Hair loss                                              13                              13.5 
Weight loss                                          0                                  0 
Hemorrhagic cystitis                           4                                 4.2 
Cardiomyopathy                                  0                                  0 
Death after Week 1                              5                                 5.2 
 
*See Table 3 for definition of toxicity scoring 
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Table 6 
Dose Reductions Following Toxicity from the University of Wisconsin 2-Year 
Chemotherapy Protocol for Canine Lymphosarcoma 
 
Drugs requiring Dosage Reductions                        No. Dogs      Percentages (%) 
 
Methotrexate                                                                      7                  7.3 
Vincristine < 0.7 mg/m2 ∗                                                   15                 15.6 
Cyclophosphamide                                                             1                  1 
Doxorubicin                                                                        1                  1 
Combined (vincristine, doxorubicin                                                                         
and cyclophosphamide)                                                       1                  1 
∗Excluding dogs reduced at Week one 
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Figure 1 – Kaplan-Meier median remission duration data comparing hypercalcemic 
and normocalcemic dogs with lymphoma that were treated with the University of 
Wisconsin 2-year chemotherapy protocol. Median remission durations were 139 ± 
20.3 days, and 296 ± 31.2 days respectively ( P = 0.017). 
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Figure 2 – Kaplan-Meier median remission duration data comparing dogs with 
lymphosarcoma classified as World Health Organization stages I-III and dogs 
classified as stages IV-VI. Median remission durations are 327 ± 9.5 days and 207 ± 
83.2 days respectively (P = 0.018). 
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Figure 3 – Kaplan-Meier median second remission duration data comparing dogs 
treated with lomustine (60 mg/m2 per os q 3 weeks) with dogs treated with the 
University of Madison 2-year chemotherapy protocol at relapse. Median second 
remission durations were 29 ± 15.1 days and 60 ± 8.7 days respectively (P = 0.008). 
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